Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Zhejiang Medicine Collaborates with Ambrx and WuXi on Breast Cancer Drug

publication date: Jun 17, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Zhejiang Medicine Co. formed a collaboration with Ambrx of San Diego to develop an Ambrx molecule that targets Her2-positive breast cancer. Ambrx genetically engineers proteins that contain new amino acids with different properties than those of the 20 natural-occurring amino acids. The company’s technology is centered on antibody-drug conjugates, which combine a targeting agent and a cytotoxic. In return for China rights, Zhejiang will underwrite the costs of development, which will be carried out by WuXi PharmaTech. More details....

Stock Symbols: (SHA: 600216) (NYSE: WX)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners